

Stroke prevention in atrial fibrillation: Past, present and

Thrombosis and Haemostasis

117, 1230-1239

DOI: [10.1160/th16-11-0876](https://doi.org/10.1160/th16-11-0876)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. American Journal of Medicine, 2017, 130, 773-779.	0.6	6
2	The ABC pathway: an integrated approach to improve AF management. Nature Reviews Cardiology, 2017, 14, 627-628.	6.1	419
3	Is atrial fibrillation another manifestation of organ damage in diabetes?. Lancet Diabetes and Endocrinology, the, 2017, 5, 761-762.	5.5	1
4	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. American Journal of Hypertension, 2017, 30, 1063-1065.	1.0	13
5	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. American Journal of Medicine, 2017, 130, 1388-1396.e6.	0.6	172
6	Direct oral anticoagulant reversal: how, when and issues faced. Expert Review of Hematology, 2017, 10, 1005-1022.	1.0	4
7	Atrial fibrillation and hypertrophic cardiomyopathy: co-existing conditions with additive risks. Hellenic Journal of Cardiology, 2017, 58, 340-341.	0.4	6
8	The role of atrial fibrillation in patients with an embolic stroke of unknown source (ESUS). Thrombosis and Haemostasis, 2017, 117, 1833-1835.	1.8	13
9	Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. Hematology American Society of Hematology Education Program, 2017, 2017, 136-143.	0.9	4
10	Long-term bleeding risk prediction in "real world"™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thrombosis and Haemostasis, 2017, 117, 1848-1858.	1.8	56
11	Thrombosis and Haemostasis: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1217-1218.	1.8	5
12	Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thrombosis and Haemostasis, 2018, 47, 768-777.	1.8	123
14	Role of chronic kidney disease and atrial fibrillation in outcomes of patients with ischemic stroke. European Journal of Neurology, 2018, 25, 1009-1010.	1.7	4
15	Comparing Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) to Different Coumadins: The Win-Win Scenarios. Thrombosis and Haemostasis, 2018, 118, 803-805.	1.8	7
16	Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. International Journal of Cardiology, 2018, 254, 157-161.	0.8	62
17	Optimizing bleeding risk assessment in patients with atrial fibrillation: To score or not to score?. International Journal of Cardiology, 2018, 254, 164-166.	0.8	0
18	Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. Journal of Alzheimer's Disease, 2018, 61, 1129-1132.	1.2	13
19	Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants. American Heart Journal, 2018, 198, 166-168.	1.2	5

#	ARTICLE	IF	CITATIONS
20	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 537-541.	1.6	7
21	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1404-1406.	1.0	10
22	Editors' Choice in the 60th Anniversary Year of Thrombosis and Haemostasis: Past, Present and Future. <i>Thrombosis and Haemostasis</i> , 2018, 118, 225-227.	1.8	1
23	Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1296-1304.	1.8	97
24	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018, 132, 149-159.	3.1	9
25	Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 341-348.	0.6	17
26	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018, 50, 288-302.	1.5	10
27	A History of Left Atrial Appendage Occlusion. <i>Interventional Cardiology Clinics</i> , 2018, 7, 143-150.	0.2	9
28	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	4.1	89
29	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2018, 20, 895-896.	0.7	24
30	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 71-86.	1.9	8
31	2018 Korean Guideline of Atrial Fibrillation Management. <i>Korean Circulation Journal</i> , 2018, 48, 1033.	0.7	108
32	Stroke Risk Stratification for Atrial Fibrillation Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2409-2411.	1.2	17
33	Letter by Shahid and Lip Regarding Article, "Stroke Risk Factors Unique to Women". <i>Stroke</i> , 2018, 49, e290.	1.0	0
34	Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2018-2019.	1.8	15
35	Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2014-2017.	1.8	39
36	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2162-2170.	1.8	32
37	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018, 49, 2933-2944.	1.0	246

#	ARTICLE	IF	CITATIONS
38	Trends in stroke outcomes in the last ten years in a European tertiary hospital. <i>BMC Neurology</i> , 2018, 18, 164.	0.8	33
39	Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ DS ₂ -VASc Score Rather Than CHA ₂ DS ₂ -VASc?" <i>Circulation</i> , 2018, 138, 443-444.	1.6	0
40	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation—The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 2983-2991.	0.7	16
41	Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1999-2009.	0.9	2
42	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.	0.7	7
43	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores. <i>Journal of the American Heart Association</i> , 2018, 7, e009766.	1.6	23
44	Ideal Blood Pressure in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1233-1245.	1.2	101
45	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1063-1071.	0.6	5
46	The Importance and Future of Population Screening for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1407-1411.	0.8	2
48	A Happy New Year from a 60-Year-Old Journal "Thrombosis and Haemostasis"! <i>Thrombosis and Haemostasis</i> , 2018, 118, 001-003.	1.8	1
49	Anticoagulation Resumption After Intracerebral Hemorrhage. <i>Current Atherosclerosis Reports</i> , 2018, 20, 32.	2.0	41
50	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , 2018, 35, 1134-1135.	1.2	1
51	Oral anticoagulation and comorbidities; too many details for clinical practice?. <i>International Journal of Cardiology</i> , 2018, 264, 93-94.	0.8	1
52	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 847-855.	0.4	4
53	Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1123-1126.	1.8	2
54	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018, 50, 511-518.	1.5	12
55	Predicting incident atrial fibrillation in patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2018, 269, 194-195.	0.8	1
56	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , 2018, 268, 137-142.	0.8	22

#	ARTICLE	IF	CITATIONS
57	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. Korean Circulation Journal, 2018, 48, 665.	0.7	44
58	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. International Journal of Cardiology, 2018, 269, 182-191.	0.8	53
59	Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation. Stroke, 2018, 49, 1872-1879.	1.0	33
60	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function. Internal and Emergency Medicine, 2018, 13, 1059-1067.	1.0	17
61	Edoxaban in Asian Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 838-853.	1.2	93
62	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. American Journal of Medicine, 2018, 131, 1359-1366.e6.	0.6	129
63	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
64	Screening for atrial fibrillation: look harder, look longer, and improve stroke outcomes with oral anticoagulation. Europace, 2018, 20, f278-f279.	0.7	3
65	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace, 2018, 20, 1382-1387.	0.7	15
66	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. Trends in Cardiovascular Medicine, 2019, 29, 150-152.	2.3	1
67	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). International Journal of Cardiology, 2019, 274, 126-131.	0.8	9
68	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	0.7	209
69	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating "valvular heart disease"™ in a nationwide cohort study. Europace, 2019, 21, 33-40.	0.7	27
70	Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding. Expert Review of Hematology, 2019, 12, 845-855.	1.0	5
71	The impact of cardiovascular diseases and new gene variants in swaying Alzheimer's™ disease. Cardiovascular Research, 2019, 115, e102-e104.	1.8	4
72	Triple or dual antithrombotic therapy post-percutaneous coronary intervention: Which one is better?. Journal of Cardiovascular Electrophysiology, 2019, 30, 2473-2474.	0.8	0
73	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace, 2019, 21, 1603-1604.	0.7	61
74	Kerala Atrial Fibrillation Registry: a prospective observational study on clinical characteristics, treatment pattern and outcome of atrial fibrillation in Kerala, India, cohort profile. BMJ Open, 2019, 9, e025901.	0.8	7

#	ARTICLE	IF	CITATIONS
75	Clinical factors and imaging leading to risk of incident atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 988-989.	0.5	0
76	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126
77	Illustrated State of the Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
78	Estándares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 1-43.	0.4	8
79	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. <i>CJC Open</i> , 2019, 1, 245-255.	0.7	2
80	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019, 21, 1633-1638.	0.7	15
81	Identification of Markers Associated With Development of Stroke in "Clinically Low-Risk" Atrial Fibrillation Patients. <i>Journal of the American Heart Association</i> , 2019, 8, e012697.	1.6	26
82	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019, 83, 2434-2442.	0.7	6
83	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. <i>Journal of Human Hypertension</i> , 2019, 33, 824-836.	1.0	55
84	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2330-2331.	1.2	0
85	A Time to Stop and Think Before the Shock. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2275-2277.	1.2	1
86	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2204-2215.	1.2	94
87	Association between epicardial adipose tissue and embolic stroke after catheter ablation of atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2209-2216.	0.8	9
88	Atrial Fibrillation in Older People: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2019, 6, 175.	1.2	56
89	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.	1.8	57
90	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2365-2375.	1.2	294
91	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1550-1552.	1.8	2
92	A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1119-1125.	1.0	2

#	ARTICLE	IF	CITATIONS
93	Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?. <i>European Heart Journal</i> , 2019, 40, 3754-3756.	1.0	2
94	Community screening for atrial fibrillation in the era of smart devices. <i>International Journal of Cardiology</i> , 2019, 280, 95-96.	0.8	0
95	Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process. <i>Canadian Journal of Cardiology</i> , 2019, 35, 611-618.	0.8	32
96	Atrial Fibrillation and Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2019, 73, 612-619.	1.2	133
97	Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 285-293.	1.8	37
98	Using Blood Biomarkers to Identify Atrial Fibrillation-Related Stroke. <i>Stroke</i> , 2019, 50, 1956-1957.	1.0	4
99	Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 879-885.	0.7	29
100	Response. <i>Chest</i> , 2019, 155, 1307.	0.4	0
101	Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011358.	1.6	38
102	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019, 156, 529-543.	0.4	94
103	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1662-1671.	1.3	41
104	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. <i>Lancet Neurology</i> , The, 2019, 18, 653-665.	4.9	143
105	Long-Term Impact of Newly Diagnosed Atrial Fibrillation During Critical Care. <i>Chest</i> , 2019, 156, 518-528.	0.4	13
106	Atrial Fibrillation and End-Stage COPD. <i>Chest</i> , 2019, 155, 888-889.	0.4	1
107	Stroke Prophylaxis for Atrial Fibrillation? To Prescribe or Not to Prescribe? A Qualitative Study on the Decisionmaking Process of Emergency Department Providers. <i>Annals of Emergency Medicine</i> , 2019, 74, 759-771.	0.3	12
108	Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2301-2303.	1.6	2
109	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.	1.0	48
110	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. <i>Stroke</i> , 2019, 50, 1480-1489.	1.0	19

#	ARTICLE	IF	CITATIONS
111	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAFâ€‘App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019, 73, e13352.	0.8	56
112	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. <i>Scientific Reports</i> , 2019, 9, 6690.	1.6	15
113	Anticoagulation for Atrial Fibrillation in Older Adultsâ€‘Using Big Data for Big Questions. <i>Thrombosis and Haemostasis</i> , 2019, 119, 855-857.	1.8	4
114	Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially â€‘Low-Riskâ€™™ Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1162-1170.	1.8	67
115	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
116	Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 55-61.	1.0	8
117	Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13103.	1.7	5
118	Etiological Research Using Observational Data, and Net Clinical Benefit. Simplicity and Practicality Matter. <i>American Journal of Medicine</i> , 2019, 132, 671-672.	0.6	0
119	Physician Estimation of Thrombotic and Bleeding Risks in Atrial Fibrillation: Letâ€™™s Talk About Sex. <i>Canadian Journal of Cardiology</i> , 2019, 35, 145-146.	0.8	1
120	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. <i>Stroke</i> , 2019, 50, 1140-1148.	1.0	39
121	Nonâ€™™ Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 939-946.	1.0	34
122	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	0.7	10
123	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. <i>American Journal of Cardiology</i> , 2019, 123, 1921-1926.	0.7	7
124	Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades. <i>Thrombosis and Haemostasis</i> , 2019, 119, 685-687.	1.8	3
125	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 381-398.	1.5	34
126	Predicting the Quality of Warfarin Therapy: Reframing the Question. <i>Thrombosis and Haemostasis</i> , 2019, 119, 509-511.	1.8	5
127	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	0.8	48
128	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and â€‘Lowâ€™™ Body Weight. <i>Journal of the American College of Cardiology</i> , 2019, 73, 919-931.	1.2	72

#	ARTICLE	IF	CITATIONS
129	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
130	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. <i>Thrombosis and Haemostasis</i> , 2019, 119, 355-357.	1.8	12
131	EHRA White Paper: knowledge gaps in arrhythmia management—status 2019. <i>Europace</i> , 2019, 21, 993-994.	0.7	40
132	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
133	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
134	Differences in outcomes between oral anticoagulation “new starters” and “switchers” in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials. <i>Journal of Arrhythmia</i> , 2019, 35, 815-820.	0.5	0
135	Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 283.	0.7	10
136	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , 2019, 8, 331.	2.5	2
137	Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 701-710.	1.3	24
138	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	1.1	8
139	Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 491-498.	0.8	8
140	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019, 48, 236-243.	0.8	6
141	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2019, 8, 2228.	1.0	24
142	Novel Echocardiographic Biomarkers in the Management of Atrial Fibrillation. <i>Current Cardiovascular Imaging Reports</i> , 2019, 12, 1.	0.4	8
143	One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. <i>International Journal of Cardiology</i> , 2019, 274, 158-162.	0.8	13
144	Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 97-98.	0.4	0
145	Anticoagulation in elderly patients with nonvalvular atrial fibrillation: A balancing act. <i>Heart Rhythm</i> , 2019, 16, 38-40.	0.3	5
146	Stroke prevention in atrial fibrillation: State of the art. <i>International Journal of Cardiology</i> , 2019, 287, 201-209.	0.8	13

#	ARTICLE	IF	CITATIONS
147	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	1.1	19
148	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	1.4	89
149	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
150	Response by Chao et al to Letter Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study". <i>Circulation</i> , 2019, 139, 146-147.	1.6	1
151	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019, 132, 856-861.	0.6	67
152	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy. <i>Chest</i> , 2019, 155, 354-363.	0.4	56
153	Anticoagulación oral en pacientes con fibrilación auricular e insuficiencia renal terminal: ¿qué es lo más apropiado? Respuesta. <i>Revista Española De Cardiología</i> , 2019, 72, 97-98.	0.6	0
154	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. <i>International Journal of Clinical Practice</i> , 2019, 73, e13285.	0.8	11
155	The prothrombotic state in atrial fibrillation: pathophysiological and management implications. <i>Cardiovascular Research</i> , 2019, 115, 31-45.	1.8	71
156	Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation. <i>American Heart Journal</i> , 2019, 208, 120-122.	1.2	5
157	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 183-188.	0.2	3
158	Risk assessment and management of atrial fibrillation patients with left atrial thrombus. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1-3.	0.5	1
159	Time trends in use of the CHADS ₂ and CHA ₂ DS ₂ -VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference. <i>International Journal of Clinical Practice</i> , 2019, 73, e13280.	0.8	8
160	Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 91-92.	2.3	1
161	Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 500-508.	0.8	8
162	Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 125-137.	1.0	11
163	Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 726-728.	0.8	5
164	Understanding family involvement in body donation in Hong Kong: A qualitative study of registered donors and bereaved family members. <i>Health and Social Care in the Community</i> , 2020, 28, 270-278.	0.7	14

#	ARTICLE	IF	CITATIONS
165	Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation: Long-term results of a multicenter study. <i>Heart Rhythm</i> , 2020, 17, 175-181.	0.3	38
166	Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. <i>Thrombosis and Haemostasis</i> , 2020, 120, 005-007.	1.8	4
167	Atrial Fibrillation in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 107-120.	1.0	3
168	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2020, 109, 802-809.	1.5	6
169	Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1018-1024.	1.5	2
170	One-year all-cause mortality risk among atrial fibrillation patients in Middle East with and without diabetes: The Gulf SAFE registry. <i>International Journal of Cardiology</i> , 2020, 302, 47-52.	0.8	6
171	Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices. <i>Europace</i> , 2020, 22, 173-176.	0.7	4
172	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. <i>IJC Heart and Vasculature</i> , 2020, 26, 100461.	0.6	1
173	Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation. <i>Chest</i> , 2020, 157, 1266-1277.	0.4	33
174	Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. <i>Stroke</i> , 2020, 51, 416-423.	1.0	42
175	Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. <i>European Journal of Heart Failure</i> , 2020, 22, 136-138.	2.9	3
176	Temporal trends of catheter ablation for patients with atrial fibrillation: A Korean nationwide population-based study. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2616-2625.	0.8	6
177	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. <i>American Heart Journal</i> , 2020, 229, 81-91.	1.2	11
178	Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 405-414.	1.4	18
179	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.	0.9	3
180	Optimizing prognosis in atrial fibrillation: A call to action in Portugal. <i>Revista Portuguesa De Cardiologia</i> , 2020, , .	0.2	0
181	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.	1.0	11
182	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 587-600.	0.6	5

#	ARTICLE	IF	CITATIONS
183	Frailty and Anticoagulant Therapy in Patients Aged 65 Years or Older with Atrial Fibrillation. <i>Cardiovascular Innovations and Applications</i> , 2020, 4, 153-161.	0.1	2
184	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
185	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Mortality and Adverse Cardiovascular Outcomes of Patients on Hemodialysis. <i>American Journal of Nephrology</i> , 2020, 51, 635-640.	1.4	16
186	Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. <i>Journal of the American Heart Association</i> , 2020, 9, e016271.	1.6	5
187	Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-10.	0.5	0
188	Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2713.	1.0	6
189	Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1151-1160.	1.8	12
190	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA ₂ DS ₂ -VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1107-1114.	1.8	4
191	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.	1.4	8
192	Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2020, 95, 929-943.	1.4	20
193	Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1485.	1.0	10
194	Ischemic Stroke in Patients With Sinus Node Disease, Atrial Fibrillation, and Other Cardiac Conditions. <i>Stroke</i> , 2020, 51, 1674-1681.	1.0	15
195	Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population. <i>Stroke</i> , 2020, 51, 1772-1780.	1.0	19
196	Comparison of Dabigatran Plus a P2Y ₁₂ Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	0.6	1
197	No free lunch—the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI. <i>Annals of Translational Medicine</i> , 2020, 8, 516-516.	0.7	0
198	Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. <i>JAMA Network Open</i> , 2020, 3, e206424.	2.8	37
199	Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1286.	1.0	19
200	Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA ₂ DS ₂ -VASc versus CHA ₂ DS ₂ -VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. <i>Thrombosis and Haemostasis</i> , 2020, 120, 894-898.	1.8	26

#	ARTICLE	IF	CITATIONS
201	Blood pressure targets in atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 2860-2862.	1.0	2
202	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Europace</i> , 2020, 22, 1147-1148.	0.7	62
203	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> , 2020, 36, 553-607.	0.5	40
204	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Heart Rhythm</i> , 2020, 17, e269-e316.	0.3	15
205	Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: A nationwide cohort study. <i>Heart Rhythm</i> , 2020, 17, 1745-1751.	0.3	11
206	Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians. <i>International Journal of Angiology</i> , 2020, 29, 088-097.	0.2	3
207	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005894.	0.9	17
208	Comparing TEEâ€•vs Nonâ€•TEEâ€•guided cardioversion of atrial fibrillation: The ENSUREâ€•AF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13221.	1.7	2
209	Should We Adopt a Standard International Normalized Ratio Range of 2.0 to 3.0 for Asian Patients with Atrial Fibrillation? An Appeal for Evidence-Based Management, Not Eminence-Based Recommendations. <i>Thrombosis and Haemostasis</i> , 2020, 120, 366-368.	1.8	12
210	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. <i>International Heart Journal</i> , 2020, 61, 231-238.	0.5	6
211	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. <i>Thrombosis and Haemostasis</i> , 2020, 120, 369-371.	1.8	11
212	Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologistâ€™s perspective. <i>Journal of Nephrology</i> , 2020, 33, 483-495.	0.9	13
213	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 357-365.	1.0	3
214	Avoiding Stroke: A Continuous Monitoring Challenge. <i>Cerebrovascular Diseases</i> , 2020, 49, 121-123.	0.8	1
215	Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. <i>Cardiovascular Diabetology</i> , 2020, 19, 30.	2.7	16
216	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020, 9, 1969.	1.0	11
217	Antithrombotic therapy in coronary artery disease patients with atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 323.	0.7	5
218	Is epicardial fat thickness associated with acute ischemic stroke in patients with atrial fibrillation?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104900.	0.7	4

#	ARTICLE	IF	CITATIONS
219	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 194-196.	1.8	0
220	The History of the Left Atrial Appendage Occlusion. <i>Cardiac Electrophysiology Clinics</i> , 2020, 12, 1-11.	0.7	10
221	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020, 22, 496-505.	0.7	29
222	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 348-357.	0.4	39
223	Association of relative wall thickness of left ventricle with incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 273-283.	1.8	10
224	Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKAN-AF survey. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13200.	1.7	5
225	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1234.	1.0	24
226	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f81-f83.	1.4	8
227	Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f84-f92.	1.4	6
228	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f3-f10.	1.4	13
229	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16
230	Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. <i>International Journal of Stroke</i> , 2021, 16, 217-221.	2.9	576
231	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021, 134, 67-75.e5.	0.6	0
232	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. <i>Journal of Internal Medicine</i> , 2021, 289, 42-52.	2.7	35
233	Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study. <i>Canadian Journal of Cardiology</i> , 2021, 37, 113-121.	0.8	3
234	Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 581-588.	0.7	7
235	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. <i>Annals of Medicine</i> , 2021, 53, 17-25.	1.5	18
236	Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13436.	1.7	45

#	ARTICLE	IF	CITATIONS
237	Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. <i>Thrombosis Research</i> , 2021, 197, 69-76.	0.8	1
238	Stroke prevention strategies in high-risk patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2021, 18, 276-290.	6.1	36
239	A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. <i>Future Cardiology</i> , 2021, 17, 215-226.	0.5	2
240	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021, 121, 270-278.	1.8	118
241	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 31-39.	1.4	5
242	Thoracoscopic Left Atrial Appendage Excision Plus Ablation for Atrial Fibrillation to Prevent Stroke. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 61-67.	0.4	7
243	Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study. <i>Cardiovascular Diabetology</i> , 2021, 20, 20.	2.7	22
244	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1061-1070.	0.9	6
245	Diabetes mellitus and atrial fibrillation—Untying the Gordian Knot. , 2021, , 95-121.		1
246	Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (>85 years) Patients With Newly Diagnosed Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2021, 96, 52-65.	1.4	21
247	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. <i>Stroke</i> , 2021, 52, 521-530.	1.0	18
248	Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. <i>Advances in Therapy</i> , 2021, 38, 2391-2405.	1.3	2
249	Atrial Fibrillation and Stroke. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 243-255.	0.7	23
250	Interpretable morphological features for efficient single-lead automatic ventricular ectopy detection. <i>Journal of Electrocardiology</i> , 2021, 65, 55-63.	0.4	6
251	Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 679-689.	1.3	10
252	Renal Disease and Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 95-112.	0.7	6
253	Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 23-33.	1.5	17
254	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. <i>Cardiovascular Research</i> , 2021, 117, 1-21.	1.8	67

#	ARTICLE	IF	CITATIONS
255	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021, 86, 1-11.	1.0	40
256	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. <i>PLoS ONE</i> , 2021, 16, e0249524.	1.1	6
257	Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. <i>Stroke</i> , 2021, 52, 1225-1233.	1.0	26
258	Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. <i>Clinical Cardiology</i> , 2021, 44, 917-924.	0.7	7
259	Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2021, 36, 793-812.	2.5	12
260	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , 2021, 23, 1511-1527.	0.7	21
262	Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 871-877.	0.3	17
263	How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1807-1810.	0.9	2
264	Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. <i>Frontiers in Pharmacology</i> , 2021, 12, 673302.	1.6	5
265	Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. <i>Europace</i> , 2022, 24, 4-11.	0.7	2
266	Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents. <i>Journal of Clinical Medicine</i> , 2021, 10, 3370.	1.0	2
267	Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. <i>Journal of Arrhythmia</i> , 2021, 37, 990-1006.	0.5	19
268	Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage. <i>Journal of Neurotrauma</i> , 2021, 38, 1791-1798.	1.7	10
269	The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2021, 10, 65-67.	1.3	18
270	Wearable cardiac monitoring using smart-devices for the detection of atrial fibrillation in adults. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
271	Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2021, 85, 1245-1253.	0.7	5
272	Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 588-595.	1.8	12
273	Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 435-446.	0.9	3

#	ARTICLE	IF	CITATIONS
274	Optimizing prognosis in atrial fibrillation: A call to action in Portugal. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 595-605.	0.2	0
275	Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. <i>JAMA Network Open</i> , 2021, 4, e2120064.	2.8	27
276	A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. <i>Annals of Pharmacotherapy</i> , 2022, 56, 691-703.	0.9	8
277	A review of patient-led data acquisition for atrial fibrillation detection to prevent stroke. <i>Biomedical Signal Processing and Control</i> , 2021, 69, 102818.	3.5	7
278	Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. <i>American Heart Journal</i> , 2021, 242, 123-131.	1.2	7
279	Diagnóstico de Fibrilação Atrial na Comunidade Utilizando Eletrocardiograma e Autorrelato: Análise Transversal do ELSA-Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 426-434.	0.3	9
280	Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A meta-analysis and systematic review. <i>IJC Heart and Vasculature</i> , 2021, 36, 100850.	0.6	2
281	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020, 133, 1195-1202.e2.	0.6	80
282	Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry. <i>Medical Science Monitor</i> , 2019, 25, 2649-2657.	0.5	22
283	Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. <i>Medical Science Monitor</i> , 2019, 25, 4691-4698.	0.5	11
284	Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. <i>Annals of Translational Medicine</i> , 2017, 5, 465-465.	0.7	3
285	Management of atrial fibrillation: easy as ABC. <i>Minerva Medica</i> , 2019, 110, 27-34.	0.3	3
286	Risk Factor Management for Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2019, 49, 794.	0.7	31
287	Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2022, 17, 848-854.	2.9	5
288	Atrial Fibrillation and Hypertrophic Cardiomyopathy. , 0, , 196-196.		0
289	The 2018 Korean Heart Rhythm Society Guidelines for Integrated Management of Korean patients with Nonvalvular Atrial Fibrillation. <i>Korean Journal of Medicine</i> , 2018, 93, 336-343.	0.1	2
290	Tackling anti-coagulation under-prescription in the elderly. <i>Aging</i> , 2019, 11, 1070-1072.	1.4	0
291	Perspectives on Atrial Fibrillation in Acute Heart Failure Position Statement: Mechanisms and Therapeutic Approach. <i>Anatolian Journal of Cardiology</i> , 2020, 23, 308-311.	0.5	1

#	ARTICLE	IF	CITATIONS
292	Awareness of stroke risk factors, warning symptoms, and significance of acute management and prevention in Qassim, Saudi Arabia. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 2158-2163.	0.1	2
293	Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2893-2904.	1.8	7
294	Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics. <i>Thrombosis Research</i> , 2021, 209, 115-116.	0.8	0
295	VARIABILITY OF BLOOD PRESSURE IN COMORBIDITY OF ARTERIAL HYPERTENSION AND ATRIAL FIBRILLATION. <i>Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta</i> , 2021, 19, 481-488.	0.0	0
296	Diagnostic Value of Atrial Fibrillation by Built-in Electrocardiogram Technology in a Blood Pressure Monitor. <i>Circulation Reports</i> , 2020, 2, 345-350.	0.4	5
298	Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 612-620.	0.2	1
299	Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 523-530.	0.7	11
300	Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP AF Long-term General Registry. <i>European Journal of Clinical Investigation</i> , 2021, , e13709.	1.7	0
301	Management of stable coronary artery disease and atrial fibrillation with anti-thrombotic therapy. <i>Medicine (United States)</i> , 2021, 100, e27498.	0.4	3
302	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score-Matched Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 352.	1.0	10
303	Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. <i>Stroke</i> , 2022, 53, 1873-1882.	1.0	18
304	Longitudinal outcomes in cryptogenic stroke patients with and without long-term cardiac monitoring for atrial fibrillation. <i>Heart Rhythm O2</i> , 2022, 3, 223-230.	0.6	5
305	The Research Progress of Decreptitude and Cognitive Impairment in Elderly Patients with Atrial Fibrillation in Plateau. <i>Advances in Clinical Medicine</i> , 2022, 12, 2315-2323.	0.0	0
306	New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin. <i>Medicine (United States)</i> , 2022, 101, e25836.	0.4	2
307	Effects of Dabigatran on Dementia Pathogenesis and Neuropsychological Function: A Review. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1589-1601.	1.2	4
308	Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2022, 12, 3413.	1.6	3
309	Undertreatment of Anticoagulant Therapy in Hospitalized Acute Ischemic Stroke Patients With Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841020.	1.1	3
310	Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document. <i>Journal of Personalized Medicine</i> , 2022, 12, 469.	1.1	8

#	ARTICLE	IF	CITATIONS
311	Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
312	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 548-559.	1.5	12
313	Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13788.	1.7	5
314	Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3847-3855.	1.1	4
315	Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation. <i>Modern Medical Technologies</i> , 2021, , 41-46.	0.1	0
316	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. <i>Medicina Clínica</i> , 2021, , .	0.3	1
317	Atrial Fibrillation in Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, 245-258.	0.9	1
319	Review of the guidelines of the European society of cardiology 2020 for the diagnosis and treatment of atrial fibrillation. , 2022, 1, 93-104.		0
320	Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	0
321	Sex-Related Differences in Left Atrial Low-Voltage Areas According to CHA2DS2-VA Scores among Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3111.	1.0	2
322	High Prevalence of Atrial Fibrillation in a Lithuanian Stroke Patient Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 800.	0.8	1
323	The Role of microRNA in the Development, Diagnosis, and Treatment of Cardiovascular Disease: Recent Developments. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 123-132.	1.3	20
324	Effectiveness and safety of oral anticoagulant therapy in patients with atrial fibrillation with prior gastrointestinal bleeding: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
325	Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. <i>Europace</i> , 2022, 24, 1739-1753.	0.7	12
326	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 177-182.	0.1	0
327	Mechanism of action of antiarrhythmic drugs. , 2023, , 289-327.		0
328	Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	0
329	Catheter ablation and cognitive function in atrial fibrillation: A systematic review and meta-analysis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2

#	ARTICLE	IF	CITATIONS
330	INFLUENCE OF METABOLIC THERAPY ON LIFE QUALITY IN PATIENTS WITH ATRIAL FIBRILLATION PAROXYSMS. Modern Medical Technologies, 2022, , 4-9.	0.1	0
332	Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper. Europace, 2023, 25, 185-198.	0.7	31
333	Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis. Baylor University Medical Center Proceedings, 0, , 1-2.	0.2	0
334	Atrial fibrillation and stroke. Expert Review of Cardiovascular Therapy, 2023, 21, 35-56.	0.6	13
335	Stroke in hemodialysis patients and its association with CHA2DS2-VASC and HAS-BLED scores: a retrospective study. CKJ: Clinical Kidney Journal, 2023, 16, 596-602.	1.4	1
336	UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey. BMC Nephrology, 2023, 24, .	0.8	6
337	Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke. Cardiovascular Drugs and Therapy, 0, , .	1.3	1
338	Safety, pharmacokinetics and exploratory exposure-response analysis of CX3002, a novel inhibitor of Xa, in Chinese healthy subjects. European Journal of Pharmaceutical Sciences, 2023, 185, 106437.	1.9	2
339	Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications. International Journal of Molecular Sciences, 2023, 24, 3628.	1.8	3